Relationship between baseline bone turnover marker levels and percent change in BMD at month 12 in postmenopausal women transitioned to denosumab or continuing on long-term alendronate therapy

the most frequent side effects (84.21%). First visit before age 60 years ensures a better adherence during the FU (p=0.018). Co-morbidities reduce adherence (p=0.047). Weekly bisphosponates absuntion presents better compliance rates than daily (p=0.005). Patients with history of fractures have better adherence (p<0.001). Adherence results higher since the first year post-fracture (p=0.048) and remain higher during FU (p=0.004). Dividing population in adherent and non-adherent at the 85% MPR cut-off results that non-adherent have an RR=1.75 of fracture. Considering the 3 periods of FU, adherence seems to increase over time (84.53% – 87,64% – 91.19%; p=0.025) Major determinants of adherence already described in clinical trials and relationship between adherence and fracture risk are confirmed in this real life study. An adherence rate increase is also detected with fractures history (more motivation) and in patients in therapy from many years. Conflict of interest: None declared.